Michael Hovater, MD
Nephrology · Birmingham, ALNPI 1932360294
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Fresenius USA Marketing, Inc. at 35.5% of the total. That places this record below the midpoint for nephrology clinicians in AL, where the typical reported total is $1,897.
Across 74 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$433
- AstraZeneca$406
- Vifor Pharma, Inc.$107
- Travere Therapeutics, Inc.$75
- Otsuka America Pharmaceutical, Inc.$39
- Amgen$24
- plus $135 from 8 others
Across 4 payments — averaging $6757.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$17K
- Astrazeneca UK Limited$9K
- Akebia Therapeutics Inc$1K
What the payments were for
- Food & beverage$1,220100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 36 | $433 |
| AstraZeneca(2 entities) | 18 | $406 |
| Vifor Pharma, Inc. | 6 | $107 |
| Travere Therapeutics, Inc. | 3 | $75 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Amgen | 1 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Akebia Therapeutics Inc | 1 | $19 |
| Boston Scientific | 1 | $16 |
| Bayer | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| GSK | 1 | $13 |
| OPKO Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$114
How this compares
$1,220 in reported general payments places this provider in the 40th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 112 | $94,817 |
| VelphoroSucroferric Oxyhydroxide | 33 | $75,060 |
| JardianceEmpagliflozin | 34 | $28,446 |
| Sevelamer Carbonate | 17 | $5,369 |
| Losartan Potassium | 93 | $1,252 |
| Estradiol | 16 | $1,184 |
| Lisinopril | 152 | $1,158 |
| Hydralazine Hcl | 20 | $1,075 |
| Tamsulosin Hcl | 35 | $631 |
| Carvedilol | 66 | $605 |
| Furosemide | 48 | $409 |
| Valsartan | 18 | $382 |
| Clonidine Hcl | 14 | $374 |
| Amlodipine Besylate | 54 | $337 |
| Allopurinol | 33 | $299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $406 | $94,817112 claims |
| Fresenius USA Marketing, Inc.Velphoro | $433 | $75,06033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 164 nephrology providers in Alabama.
Other nephrology in Birmingham
- Dana RizkBirmingham$196K
- Eric WallaceBirmingham$172K
- David WarnockBirmingham$128K
- Michal MrugBirmingham$73K
- Vineeta KumarBirmingham$59K
- Ashita TolwaniBirmingham$56K
- Song Ching OngBirmingham$36K
- Orlando GutierrezBirmingham$26K
- Ammar AlmehmiBirmingham$26K
- Jared CookBirmingham$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.